In vivo CAR-T Insights Series (5) — Key Considerations in LNP Encapsulation and Method Comparison

Release Time：

2025-12-03 16:11

In in vivo CAR-T research, the design and encapsulation strategy of lipid nanoparticles (LNPs) play a decisive role in transfection efficiency and therapeutic outcomes.

🔹 Lipid Selection Principles

Ionizable lipids: Ensure stable complexation with nucleic acids and efficient intracellular release.
Helper lipids: Cholesterol, DSPC, PEG-lipids, etc., stabilize particle structure and regulate circulation time.

🔹 Different Demands for mRNA vs. pDNA

mRNA: Requires rapid release and efficient translation, emphasizing short-term, high-level expression.
pDNA: Needs stable delivery and nuclear transport, with higher requirements for structural integrity.

🔹 Encapsulation Methods

Microfluidics: High controllability, suitable for scalable and reproducible manufacturing.
Ethanol Injection: Simple and practical, often used in early-stage development.

⚡ Key Insight: The choice of lipid composition and encapsulation method not only determines the physicochemical properties of LNPs but also directly impacts T cell transfection efficiency and downstream CAR expression.

📊 Looking ahead, LNP design will be a critical driving force for the clinical translation of in vivo CAR-T therapies.

Levostar’s In vivo CAR-T Solutions

From mRNA synthesis to LNP delivery, Levostar empowers in vivo CAR-T research with speed and precision. As in vivo CAR-T advances, the design and encapsulation of lipid nanoparticles (LNPs) has become a critical factor driving delivery efficiency and therapeutic outcomes.

🌟 Levostar LNP Encapsulation Advantages

1. End-to-End Integration – from sequence to final LNP products

2. Superior Nanoparticle Characterization – QC analytics ensure precision and reliability

3. Flexible Scaling Capacity – manufacturing from 100 μg to 100 mg

4.Ready-to-Use mRNA-LNPs – 150+ pre-validated mRNA sequences available

Let’s accelerate the future of cell therapy — directly inside the body.

In vivo CAR-T Insights Series (6) — Antibody Discovery: Why use mRNA for immunity？

In vivo CAR-T Insights Series (4) — The Role of mRNA in In vivo CAR-T